Overall, the reduction of hepatic Ucp2 and Nos2 expression in DIO mice treated with PGG indicated a preventive effect on obesity but also on non-alcoholic steatohepatitis. Here, NOS2 is linked to metabolic dysfunction-associated steatohepatitis.